tbuckley/cabot-search huggingface dataset:
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Authors: Avichai Shimoni, Myriam Labopin, Jürgen Finke, Fabio Ciceri, Eric Deconinck, Nicolaus Kröger, Martin Gramatzki, Matthias Stelljes, Didier Blaise, Friedrich Stoelzel, Patrice Chevallier, Ernst Holler, Nathalie Fegueux, Mohamad Mohty, Arnon Nagler
Journal: Blood Cancer Journal (2019)

Abstract Second allogeneic stem-cell transplantation (SCT2) is a therapeutic option for patients with AML relapsing after a first transplant. Prior studies have shown similar results after SCT2 from the same or different donor; however, there are limited data on second non-T-depleted haplo-identical transplant in this setting. We retrospectively analyzed SCT2 outcomes in 556 patients, median age 46 years, relapsing after first transplant given in CR1. Patients were divided into three groups based on SCT2 donor (donor2): same donor ( n = 163, sib/sib-112, UD/UD-51), different matched donor ( n = 305, sib/different sib-44, sib/UD-93, UD/different UD-168), or haplo-donor ( n = 88, sib/haplo-45, UD/haplo-43). Two-year leukemia-free survival (LFS) rate after SCT2 was 23.5%, 23.7%, and 21.8%, respectively ( P = 0.30). Multivariate analysis showed no effect of donor2 type on relapse: hazard ratio (HR) 0.89 ( P = 0.57) and 1.11 ( P = 0.68) for different donor and haplo-donor compared to same donor, respectively. However, donor2 did predict for non-relapse mortality (NRM) after SCT2: HR 1.21 ( P = 0.50) and 2.08 ( P = 0.03), respectively, and for LFS: HR 1.00 ( P = 0.97) and 1.43 ( P = 0.07), respectively. In conclusion, SCT2 with the same or different matched donor is associated with similar outcomes in patients with relapsed AML. Non-T-depleted haplo-identical transplant may be associated with higher NRM, similar relapse rate and with no better results in this setting.
CSIG-12. PREX1 LINKS ABERRANT PI 3-KINASE PATHWAY SIGNALING TO MAINTENANCE OF THE NEURAL STEM CELL-LIKE PHENOTYPE OF GLIOBLASTOMA CELLS
Authors: Ian Lorimer, Sylvie Lavictoire, Danny Jomaa, Alex Gont, Karen Jardine
Journal: Neuro-Oncology (2019)

Abstract Virtually all primary glioblastomas have aberrant activation of the PI 3-kinase pathway through mutational inactivation of tumour suppressors such as PTEN and/or mutational activation of oncogenes. Most glioblastomas also overexpress the Rac guanine nucleotide exchange factor PREX1, which is activated by PI 3-kinase pathway signaling. To determine the role of PREX1 in mediating the effects of aberrant PI 3-kinase pathway signaling in glioblastoma, we used CRISPR/Cas9 to knockout PREX1 in patient-derived glioblastoma cells cultured under conditions that maintain their neural stem cell-like characteristics. Multiple PREX1-null glioblastoma cell clones showed reduced motility and an altered morphology, with a smaller cell body and multiple neurite-like extensions. They also had increased expression of doublecortin, a marker of committed neurogenic progenitor cells. Analysis of RNA-seq data for transcription factor usage was consistent with the acquisition of an intermediate progenitor-like phenotype in PREX1-null cells, with loss of neural stem cell-associated polycomb repressive complex 2 and DMRTA2 activity and the expression of an EOMES/TBR2 signature characteristic of intermediate progenitors. The reduced motility, altered morphology and increase in doublecortin protein levels could all be reversed by re-expression of PREX1. PREX1-null cells had a reduced ability to phosphorylate and inactivate Lgl1, which is required for the maintenance of neural stem cell-like glioblastoma cell populations in vivo. These data show that PREX1 links aberrant PI 3-kinase signaling to maintenance of the neural stem cell-like phenotype in glioblastoma cells.
Evaluation of polyvinylpyrrolidone and block copolymer micelle encapsulation of serine chlorin e6 and chlorin e4 on their reactivity towards albumin and transferrin and their cell uptake
Authors: Ilche Gjuroski, Eleftheria Girousi, Christoph Meyer, Damian Hertig, Darko Stojkov, Michaela Fux, Nicolas Schnidrig, Jan Bucher, Sara Pfister, Luca Sauser, Hans-Uwe Simon, Peter Vermathen, Julien Furrer, Martina Vermathen
Journal: Journal of Controlled Release (2019)
Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study
Authors: Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, Fernanda S Seguro, Gustavo HR Magalhaes, Nelma D Clementino, Arthur Moellmann-Coelho, Ingrid Luise, Monika Conchon, Natália N Gonçalves, Jaisson Bortolini, Laura Maria Fogliatto, Carmino Antonio Souza, Katia B Pagnano, Israel Bendit
Journal: Blood (2019)
In Vitro and inVivo Activity of Melflufen in Amyloidosis
Authors: Ken Flanagan, Muntasir M Majumder, Romika Kumari, Juho Miettinen, Ana Slipicevic, Sarah A. Holstein, Michelle L. Varney, Minna Suvela, Fredrik Lehmann, Nina N. Nupponen, Caroline A Heckman
Journal: Blood (2019)
An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies
Authors: Constantine S. Tam, Gavin Cull, Stephen Opat, Gareth P Gregory, Aichun Liu, Anna M. Johnston, Weili Zhao, Fernando Roncolato, Sasanka M. Handunnetti, H. Miles Prince, Costas K. Yannakou, Wenyu Li, Ted Shih, Xiaoping Zhang, Ken Wu, Yuan Liu, Jane Huang, Judith Trotman
Journal: Blood (2019)
Splanchnic Venous Thrombosis (SVT) Case Series at a Tertiary Care Hospital: Exploring Clinical Presentation, Diagnosis, Etiology, Thrombophilia, Treatment, and Outcome
Authors: Mohammed Abdullah Alsheef, Mukhtar Alomar, Ghaydaa Juma Kullab, Abdurahman AlTwaijri, Hassan Maymani, Abdul Rehman Z. Zaidi
Journal: Blood (2019)
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
Authors: Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler, Rebekka Wehner, Marc Schmitz, Meike Jakobi, Nicole Schneiderhan-Marra, Reinhild Klein, Karoline Laske, Kerstin Artzner, Linus Backert, Heiko Schuster, Johannes Schwenck, Alexander N. R. Weber, Bernd J. Pichler, Manfred Kneilling, Christian la Fougère, Stephan Forchhammer, Gisela Metzler, Jürgen Bauer, Benjamin Weide, Wilfried Schippert, Stefan Stevanović, Markus W. Löffler
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> We previously showed that the bacterial lipopeptide Pam<sub>3</sub>Cys-Ser-Ser, meanwhile established as a toll-like receptor (TLR) 1/2 ligand, acts as a strong adjuvant for the induction of virus specific CD8<sup>+</sup> T cells in mice, when covalently coupled to a synthetic peptide. <h3>Case presentation</h3> We now designed a new water-soluble synthetic Pam<sub>3</sub>Cys-derivative, named XS15 and characterized it in vitro by a TLR2 NF-κB luciferase reporter assay. Further, the capacity of XS15 to activate immune cells and stimulate peptide-specific CD8<sup>+</sup> T and NK cells by 6-sulfo LacNAc<sup>+</sup> monocytes was assessed by flow cytometry as well as cytokine induction using immunoassays. The induction of a functional immune response after vaccination of a volunteer with viral peptides was assessed by ELISpot assay and flow cytometry in peripheral blood cells and infiltrating cells at the vaccination site, as well as by immunohistochemistry and imaging. XS15 induced strong ex vivo CD8<sup>+</sup> and T<sub>H</sub>1 CD4<sup>+</sup> responses in a human volunteer upon a single injection of XS15 mixed to uncoupled peptides in a water-in-oil emulsion (Montanide™ ISA51 VG). A granuloma formed locally at the injection site containing highly activated functional CD4<sup>+</sup> and CD8<sup>+</sup> effector memory T cells. The total number of vaccine peptide-specific functional T cells was experimentally assessed and estimated to be 3.0 × 10<sup>5</sup> in the granuloma and 20.5 × 10<sup>6</sup> in peripheral blood. <h3>Conclusion</h3> Thus, in one volunteer we show a granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only. The ex vivo T cell responses in peripheral blood were detectable for more than one year and could be strongly boosted by a second vaccination. Hence, XS15 is a promising adjuvant candidate for peptide vaccination, in particular for tumor peptide vaccines in a personalized setting.
Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
Authors: Jerald P. Radich, Andreas Hochhaus, Francis J. Giles, David M. Ross, Giuseppe Saglio, Timothy P. Hughes, Dong-Wook Kim, Rafik Fellague-Chebra, Manu Sondhi, Ranjan Tiwari, Kaushal Mishra, Francois-Xavier Mahon
Journal: Blood (2019)
Next Generation NKG2D-based CAR T-cells (CYAD-02): Co-expression of a Single shRNA Targeting MICA and MICB Improves Cell Persistence and Anti-Tumor Efficacy in vivo
Authors: Martina Fontaine, Benjamin Demoulin, Simon Bornschein, Susanna Raitano, Steve Lenger, Hidevaldo Machado, Jonathan D Moore, Panagiota A. Sotiropoulou, David E Gilham
Journal: Blood (2019)
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Authors: Sameer A. Parikh, Eli Muchtar, Betsy Laplant, Wei Ding, Sikander Ailawadhi, Amber Koehler, Timothy G. Call, Saad S. Kenderian, Jose F. Leis, Amie Fonder, Min Shi, Asher A. Chanan-Khan, Adam Pettinger, Thomas E. Witzig, Carrie A. Thompson, Jose C Villasboas, Jessica M Sholes, Curtis A. Hanson, Esteban Braggio, Kay L. Medina, Susan L. Slager, Neil E. Kay
Journal: Blood (2019)
A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome
Authors: Abdelrahman H. Elsayed, Huiyun Wu, Xueyuan Cao, Susana C. Raimondi, James R. Downing, Raul Ribeiro, Tanja A. Gruber, Rhonda E. Ries, Soheil Meshinchi, Jeffrey Rubnitz, Stanley Pounds, Jatinder K Lamba
Journal: Blood (2019)
RARE-30. PEDIATRIC GLIOBLASTOMA IN THE POST-TEMOZOLOMIDE ERA: OUTCOMES AND CHARACTERISTICS
Authors: Ankush Chandra, Taemin Oh, Harsh Wadhwa, Sumedh Shah, Nalin Gupta, Mike McDermott, Mitchel Berger, Manish Aghi
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma (GBM) is the most common brain tumor, however, is a rare occurrence in children and is poorly characterized. We evaluated the characteristics and outcomes of pediatric GBM (pGBM). METHODS Retrospective analysis of pediatric (age&lt; 18) patients diagnosed with GBM undergoing first glioblastoma resection at our brain tumor center (2005- 2016). RESULTS From 1457 GBM patients, we identified twenty-four (1.65%) pGBMs (Median Age=9 years, Females=45.8%). Median overall survival (OS) was 32.1 months, while the median progression-free survival was 11.5 months. The commonest symptoms at presentation were headaches (54.2%,n=13) and motor symptoms (50%,n=12). Mean tumor diameter was 4.5 cm and 25% of the cohort underwent gross total resection (GTR) of their tumor. Univariate analysis revealed median OS significantly associated with tumor extent of resection (GTR=56.4 months; STR/Biopsy=13.7 months, p=0.001), age at surgery (&gt;10 years=43.9 months, &lt; 10 years= 17.2 months, p=0.01), tumor size (&gt; 4cm= 9.1 months, &lt; 4cm=56.9 months, p=0.01),motor symptoms at presentation (present=14.9 months, absent=41.04 months, p=0.02) and infratentorial tumors (infratentorial=17.4 vs supratentorial=53.4 months, p=0.02). Multivariate analysis revealed GTR (HR 0.2[95% CI 0.07–0.72]; p=0.03), Age &gt;10 years (HR 0.6[95% CI 0.02–0.64]; p=0.002), tumor &gt;4 cm (HR 2.89[95% CI 1.88–4.11]; p=0.001) and EGFR amplification (HR 3.48[95% CI 0.82–17.4]; p=0.005) to be independent predictors of OS. Comparing patients under and over 10 years, we found that older patients had smaller tumors at presentation (4.9 vs 3.6 cms, p=0.03), greater rates of preoperative temozolomide (n=1,7.7% vs n=6, 54.5%) and bevacizumab (n=1,7.7% vs n=4, 36.4%) treatment, and lower rates of EGFR amplification (66.7% vs 11.1%) that could explain survival disparities between groups. CONCLUSION Motor symptoms, larger tumors at presentation and tumor EGFR amplification may be indictive of poorer outcomes in pGBM. However, maximal tumor resection, aggressive chemoradiation and tumor presentation at age &gt;10 years may confer better prognosis in these patients.
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study
Authors: Philippe Moreau, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Facon, Xavier Leleu, Karim Belhadj, Lionel Karlin, Lotfi Benboubker, Mark-David Levin, Monique C. Minnema, Bastien Jamet, Caroline Bodet-Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Francoise Kraeber-Bodere
Journal: Blood (2019)
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Authors: Amer M. Zeidan, Michael W. Schuster, Jürgen Krauter, Johan A. Maertens, Emmanuel Gyan, Magalie Joris, Tobias F Menne, Paresh Vyas, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, Arthur Kudla, Geoffrey Chan, Mikkael A. Sekeres
Journal: Blood (2019)
CBMT-22. REVERSING THE WARBURG EFFECT BY TARGETING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT), THE RATE-LIMITING ENZYME OF NAD+ SALVAGE PATHWAY INCREASES, CHEMOSENSITIVITY TO TEMOZOLOMIDE IN GLIOMA CELLS
Authors: Pratibha Sharma, William Senapedis, Deepa Sampath, Vinay Puduvalli
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioma cells metabolize glucose primarily through incomplete, non-oxidative glycolysis even in the presence of oxygen (the Warburg effect) which provides a constant supply of substrate for proliferation and generates an acidic environment that favors invasion and immunosuppression. NAMPT, the rate-limiting enzyme of the NAD+ salvage pathway, regulates key metabolic processes preferentially used in glioma energy metabolism. Inhibition of NAMPT could have global impact on glioma cell metabolism and could be a promising strategy for glioma therapy. This study examined the effect of NAMPT inhibition using KPT-9274 and FK866 (NAMPTi) on glycolysis and glioma cell metabolism. METHODS Metabolic changes related to NAMPT inhibition were examined in glioma cell lines and patient derived glioma stem-like cells (GSC). Mass spectrometry was used for metabolic profiles and the generated data was annotated by comparison against an extensive metabolite library to identify relevant metabolites. The Agilent Seahorse assay was utilized to determine treatment-related changes in glycolysis. RESULTS NAMPT inhibition caused NAD, NADH, NADP, NADPH, and ATP depletion in glioma cells. Global metabolomics results showed an accumulation of GMP, IMP, AMP and myo-inositol indicating reprogramming of glioma cell metabolism for de novo purine biosynthesis. Additionally, an accumulation of glucose- and fructose-1,6 bisphosphate in NAMPTi treated cells indicated dysfunctional glycolysis. This was confirmed by the Agilent glycolysis stress test by which NAMPTi-treated glioma cells showed a reduction in glycolysis, glycolytic capacity and reserves. NAMPTi treated cells showed downregulation of LDHA due to NAD depletion. Further, downregulation of LDHA enhanced the chemosensitivity of glioma cells to temozolomide. CONCLUSIONS NAMPTi cause profound disruption of glycolysis, reduced glycolytic capacity and glycolytic reserve in gliomas and GSCs irrespective of O[6]-methylguanine-DNA methyltransferase promoter methylation or IDH1 status. Targeting NAMPT to disrupt the Warburg effect is a novel strategy for developing effective therapies against glioma to overcome heterogeneity.
DDIS-23. CMV-BASED PLASMID DNA VACCINE FOR GBM USING THE UNITE PLATFORM
Authors: Amit Adhikari, Barb Toll, Yoshimi Johnson, Anthony Marketon, Greg Wilson, Juliete Macauley, Teri Heiland
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is an aggressive form of brain cancer with a median survival of 15 months, remaining unchanged in spite of technological advances in the standard of care. The presence of the partial CMV genome, specifically in GBM cells, provides a great opportunity for a targeted therapy. We have utilized our UNITE (UNiversal Intracellular Targeted Expression) platform to build a polyvalent DNA vaccine which includes HCMV proteins, pp65, gB and IE-1. The UNITE platform is based, in part, on a lysosomal targeting technology which can result in increased antigen presentation, a balanced T cell response, and subsequent immunologic benefit. Using an orthotopic GBM mouse model expressing CMV proteins in the CT2A cell line, we have shown up to 45% survival when treated therapeutically with the pp65-IE-1 vaccine. In order to further improve the vaccine’s efficacy, and also to understand the mechanism of action, we are evaluating the post-vaccination tumor microenvironment and testing combination therapies with immune checkpoint inhibitors. Preliminary data on treated tumors suggest an increase in the PD-1 immune checkpoint regulator and a higher number of regulatory T cells. Our immune response evaluation of the polyvalent vaccine in naïve mice showed generation of robust antigen specific T cell activation. The use of multiple antigens in this vaccine makes it better suited to prevent antigen escape by tumor cells. Encouraged by our non-clinical data and the promising outcomes from our collaborators’ clinical trials using pp65 mRNA transfected autologous dendritic cells (ATTAC and ATTAC-II), we are moving forward with a phase I trial. We believe that the immune boost from our UNITE platform combined with deactivation of the immunosuppressive microenvironment by checkpoint inhibition holds a promising treatment against GBM.
Increased Allele Frequency of GNPAT p.D519G in Compound HFE p.C282Y/p.H63D Heterozygotes with Elevated Serum Ferritin Levels
Authors: Eriza S. Secondes, Daniel F. Wallace, Gautam Rishi, Gordon D. McLaren, Christine E. McLaren, Wen-Pin Chen, Louise Ramm, Lawrie W. Powell, Grant A. Ramm, James C. Barton, V. Nathan Subramaniam
Journal: Blood (2019)
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
Authors: Ola Landgren, Donna Mastey, Alexander M. Lesokhin, Eric L Smith, Urvi A Shah, Sham Mailankody, Malin Hultcrantz, Hani Hassoun, Sydney X Lu, Meghan Salcedo, Victoria Diab, Kelly Werner, Jenna Rispoli, Allison Sams, Dennis Verducci, Katie Jones, Julia Schlossman, Aisara Chansakul, Angela Harrison, Amanda Ciardiello, Elizabeth Tavitian, Tala Shekarkhand, Even Rustad, Venkata Yellapantula, Francesco Maura, Tim J Peterson, Sean M. Devlin, Heather J Landau, Michael Scordo, David J. Chung, Gunjan Shah, Oscar B Lahoud, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, Maria E Arcila, Caleb Ho, Mikhail Roshal, Ahmet Dogan, Sergio Giralt, Neha Korde
Journal: Blood (2019)
Interobserver Reproducibility of the Myoton and Durometer Devices to Measure Skin Stiffness and Hardness in Chronic Cutaneous Graft-Versus-Host Disease Patients
Authors: Fuyao Chen, Laura Wang, Arved Vain, Yvette Ssempijja, Laura Dellalana, Kathy Zhang, Alexis Hood, Heidi Chen, Madan Jagasia, Eric R. Tkaczyk
Journal: Blood (2019)
HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53
Authors: Caroline Capdevielle, Angélique Desplat, Justine Charpentier, Francis Sagliocco, Pierre Thiebaud, Nadine Thézé, Sandrine Fédou, Katarzyna B Hooks, Romano Silvestri, Veronique Guyonnet-Duperat, Melina Petrel, Anne-Aurélie Raymond, Jean-William Dupuy, Christophe F Grosset, Martin Hagedorn
Journal: Neuro-Oncology (2019)

Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors such as panobinostat (PS) is therefore a novel therapeutic option currently evaluated in clinical trials.BH3 profiling revealed engagement in an irreversible apoptotic process of glioma cells exposed to PS confirmed by annexin-V/propidium iodide staining. Using proteomic analysis of 3 DMG cell lines, we identified 2 proteins deregulated after PS treatment. We investigated biological effects of their downregulation by silencing RNA but also combinatory effects with PS treatment in vitro and in vivo using a chick embryo DMG model. Electron microscopy was used to validate protein localization.Scaffolding proteins EBP50 and IRSp53 were upregulated by PS treatment. Reduction of these proteins in DMG cell lines leads to blockade of proliferation and migration, invasion, and an increase of apoptosis. EBP50 was found to be expressed in cytoplasm and nucleus in DMG cells, confirming known oncogenic locations of the protein. Treatment of glioma cells with PS together with genetic or chemical inhibition of EBP50 leads to more effective reduction of cell growth in vitro and in vivo.Our data reveal a specific relation between HDAC inhibitors and scaffolding protein deregulation which might have a potential for therapeutic intervention for cancer treatment.
Physical Therapy of Mental Disorder
Authors: G. Day
Journal: BMJ (1947)

Oxygen consumption was measured in 9 short-gestation infants before feeding and for an hour after, using a closed-circuit metabolism chamber. Using the same system, O2 consumption of 9 term infants was measured for varying periods, beginning one hour from the end of the last feed. In the short-gestation infants a rise was found in the 15--45 minutes after feeding; O2 consumption then fell, and after 60 minutes had reached prefeed levels. The term infants showed no decrease with time after the first hour, as would be expected if the effect of feeding on O2 consumption extended beyond this. It is concluded that increased O2 demand after appropriate feeding does not extend beyond one hour postprandially.
Influence of CD27- CD28- T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion
Authors: Nina Worel, Katharina Pfistershammer, Winfried Pickl, Marion Heinz, Martina Schlager, Beate Pribitzer, Andreas Tanzmann, Ulrich Jaeger, Georg Hopfinger
Journal: Blood (2019)